Tcelltech CAR-T Cell Therapy Recognized by FDA Orphan Drug (ODD)

Tcelltech Announces FDA Orphan Drug Designation for Investigational B7-H3 CAR-T Therapy in Malignant Glioblastoma

June 21, 2023  Tcelltech announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Drug Development has granted Orphan Drug Designation (ODD) to the company’s investigational B7-H3-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of malignant glioblastoma.

About Orphan Drug Designation

Under the FDA Orphan Drug Act, Orphan Drug Designation provides several incentives, including FDA support for clinical research guidance, exemption of New Drug Application (NDA) fees, a fast track for marketing application in the United States, and seven years of U.S. market exclusivity following approval.

About the B7-H3 CAR-T Program

The B7-H3-targeted CAR-T cell therapy was developed by Tcelltech and is in Phase I clinical development. It has complete independent intellectual property rights. Tcelltech holds a portfolio of B7-H3-targeted CAR-T programs across multiple tumor types, including malignant glioblastoma.

Disease Background

Malignant glioblastoma is an aggressive tumor with a poor prognosis, of which glioblastoma (GBM) is the most common. GBM is associated with a median survival of approximately 14.6 months after diagnosis and a 5-year survival rate of approximately 4.7%. GBM is prone to relapse after surgery, and effective treatment options after recurrence are limited. There is a high unmet need for new treatment approaches.

Next Steps

The Orphan Drug Designation is expected to support the clinical development program for Tcelltech’s B7-H3 CAR-T therapy in China and the United States.

About Tcelltech

Tcelltech is a clinical-stage biopharmaceutical company focused on the development of T-cell immuno-oncology products. Co-founded by Prof. Chen Liping, a pioneer in tumor immunology, and Prof. Huang Gangxiong, an expert in immune cell therapy, the company is driven by a mission of research and innovation. Tcelltech has built an integrated professional team spanning the full drug development lifecycle research, technology development, quality management, manufacturing process, regulatory registration, and clinical research. The team is committed to developing immunotherapies for cancer patients with unmet medical needs.

Gangxiong Huang, MD

Co-founder, CEO

Dr. Huang’s research has focused on tumor metastasis and T-cell immunotherapy. He completed his postdoctoral training and subsequently served as a researcher at The University of Texas MD Anderson Cancer Center. He also served as a pathologist and Minjiang Scholar Professor at Fujian Medical University previously.

Lieping Chen, MD, PhD​

Co-founder, Scientific advisor

Dr. Chen is a pioneer in cancer immunotherapy. His research focuses on fundamental T-cell biology and the translation of scientific discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. He discovered PD-L1 and established its role in tumor immune evasion, laying the foundation for anti-PD-1/PD-L1 therapies that have transformed cancer treatment worldwide. Among his other numerous discoveries, B7-H3 has emerged as a promising universal therapeutic target for solid tumors. 

Dr. Chen is United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine at Yale University. He held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. Dr. Chen is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research.